Skip to main content
Clinical Trials/EUCTR2007-004757-28-GB
EUCTR2007-004757-28-GB
Active, not recruiting
Phase 1

A randomised controlled single-blind trial to compare intensive management vs standard care in early psoriatic arthritis - TICOPA

niversity of Leeds0 sites206 target enrollmentMarch 14, 2008

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
ewly diagnosed psoriatic arthritis of less than two years symptom duration
Sponsor
niversity of Leeds
Enrollment
206
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 14, 2008
End Date
May 10, 2013
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
niversity of Leeds

Eligibility Criteria

Inclusion Criteria

  • Patients with the following characteristics are eligible for the study:
  • 1\.Patients with a diagnosis of psoriatic arthritis by a consultant Rheumatologist with less than 24 months disease duration.
  • 2\.Active disease defined by at least one tender or swollen joint or active enthesitis.
  • 3\.Age \=18 years at the time of signing the informed consent form and either male or female patients.
  • 4\.Patient understands the objectives of the study and is able and willing to sign the Informed Consent Form.
  • 5\.Men and women of child bearing potential (WCBP) must use at least one adequate birth control measure for the duration of the study and should continue such precautions for 6 months after receiving the last dose of protocol treatment.
  • 6\.Adequate full blood count within 28 days before randomisation:
  • a.Haemoglobin count \> 8\.5 g/dL
  • b.White blood count (WBC) \> 3\.5 x 109/L
  • c.Absolute neutrophil count (ANC) \> 1\.5 x 109/L

Exclusion Criteria

  • Patients will be excluded from this study for any of the following reasons:
  • 1\.Previous treatment for articular disease with disease modifying drugs (DMARDs) including, but not limited to, methotrexate, sulfasalazone, leflunomide,
  • 2\.Women who are pregnant, lactating or planning pregnancy within 6 months of their last dose of protocol treatment.
  • 3\.Use of any investigational agents within 4 weeks or within 5 half\-lives of the investigational agent, whichever is longer, prior to randomisation.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
When reconstructing defects in the skull is it safer and more cost effective to use a patients own bone or a custom made titanium plate
ACTRN12612000353897Royal Perth Hospital64
Terminated
Not Applicable
A single-blinded randomised controlled trial to evaluate the pre-treatment effect of two vaginal estradiol doses compared to no treatment on the quality of pap smears in post-menopausal women.Quality of post-menopausal pap smearsNew health condition. Please modify.Reproductive Health and Childbirth - Menstruation and menopause
ACTRN12605000610639Family Planning NSW270
Completed
Not Applicable
Effectiveness of interventions in improving continued exclusive breastfeeding in Brunei Darussalam
ISRCTN55245820Ministry of Health (Brunei)232
Not yet recruiting
Not Applicable
A clinical trial to study the effects and safety of 3 drugs in varied combinations, namely 1% Luliconazole cream plus 1% Ciclopirox Olamine cream, 1% Luliconazole cream plus 0.25% Amorolfine cream and 1% Luliconazole cream alone in the treatment of ringworm, a fungal infection of skin.Health Condition 1: B354- Tinea corporis
CTRI/2022/12/048431SRM Medical College Hospital & Research Centre, SRMIST, Potheri
Completed
Not Applicable
A single blind randomised controlled trial to determine the effectiveness and cost utility of manual chest physiotherapy techniques in the management of infective exacerbations of Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)RespiratoryChronic obstructive pulmonary disease (COPD)
ISRCTN13825248niversity of East Anglia (UK)550